{"id":"clindamycin-bpo","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Peeling"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL1200588","moleculeType":"Small molecule","molecularWeight":"461.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Cutibacterium acnes. Benzoyl peroxide is an oxidizing agent that generates reactive oxygen species to kill bacteria and also helps reduce sebum production and comedone formation. The combination provides synergistic antibacterial and anti-inflammatory effects on acne lesions.","oneSentence":"Clindamycin kills acne-causing bacteria while benzoyl peroxide reduces sebum production and provides antimicrobial activity, together reducing inflammatory and comedonal acne.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:27.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris (inflammatory and comedonal)"}]},"trialDetails":[{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT03849885","phase":"PHASE4","title":"Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty","status":"UNKNOWN","sponsor":"Colorado Joint Replacement","startDate":"2019-02-02","conditions":"Degenerative Osteoarthritis","enrollment":496},{"nctId":"NCT00441415","phase":"PHASE3","title":"Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Acne Vulgaris","enrollment":272},{"nctId":"NCT02616614","phase":"PHASE3","title":"Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-05","conditions":"Acne Vulgaris","enrollment":862},{"nctId":"NCT02578043","phase":"PHASE1","title":"A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":844},{"nctId":"NCT01445301","phase":"PHASE3","title":"Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-27","conditions":"Acne Vulgaris","enrollment":800},{"nctId":"NCT02058628","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-21","conditions":"Acne Vulgaris","enrollment":222},{"nctId":"NCT00757523","phase":"PHASE4","title":"Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-09-10","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT01132443","phase":"PHASE1","title":"W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-05-06","conditions":"Acne Vulgaris","enrollment":72},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT00837213","phase":"PHASE4","title":"Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-08","conditions":"Acne","enrollment":33},{"nctId":"NCT00891982","phase":"PHASE3","title":"A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04-01","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT01015638","phase":"PHASE4","title":"Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":36},{"nctId":"NCT00776919","phase":"PHASE3","title":"Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-10","conditions":"Acne Vulgaris","enrollment":1315},{"nctId":"NCT00926367","phase":"PHASE4","title":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT01400932","phase":"PHASE3","title":"Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07","conditions":"Acne Vulgaris","enrollment":360}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BURNING SENSATION"},{"count":1,"reaction":"CHEMICAL BURN OF SKIN"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRY EYE"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"EYE SWELLING"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Clindamycin + BPO","genericName":"Clindamycin + BPO","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin, a small molecule bacterial 70S ribosome inhibitor, is used in combination with benzoyl peroxide to treat acne vulgaris. This combination is available in a 1.2%/3.75% gel formulation, such as Onexton, which has been studied in clinical trials for its effectiveness in treating acne.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}